US2021100764A1PendingUtilityA1

Methods of treating mixed dyslipidemia

79
Assignee: AMARIN PHARMACEUTICALS IE LTDPriority: Apr 29, 2009Filed: Dec 18, 2020Published: Apr 8, 2021
Est. expiryApr 29, 2029(~2.8 yrs left)· nominal 20-yr term from priority
Inventors:Ian OsterlohPierre WickerRene BraeckmanParesh SoniMehar Manku
A61K 9/4858A61K 9/127A61K 45/06A61K 31/202A61K 9/48A61K 9/20A61P 9/00A61P 3/10A61P 3/06A61P 3/04A61P 25/28A61P 1/16A61P 9/04A61K 47/22A61P 7/12A61K 31/505A61P 31/18A61K 31/22A61K 31/40A61K 31/222A61P 9/10A61P 9/06A61P 7/02A61P 9/12A61K 31/155A61K 47/34A61K 31/232A61K 31/397A61K 31/405A61P 3/08A61K 31/74A61K 31/47A61K 47/26A61K 31/337A61K 2121/00A61P 3/00A61K 31/366
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Claims

exact text as granted — not AI-modified
I/We claim: 
     
         1 . A method of reducing triglycerides in a subject with atrial fibrillation and triglyceride levels of greater than 500 mg/dl, said method comprising administering to said subject an effective amount of icosapent ethyl for a period of time effective to reduce triglyceride levels, whereby said administration also reduces risk of stroke in said subject. 
     
     
         2 . The method of  claim 1 , wherein the subject is on statin therapy. 
     
     
         3 . The method of  claim 1 , wherein the subject has a baseline LDL-C level of about 40 mg/dL to about 100 mg/dL. 
     
     
         4 . The method of  claim 1 , wherein the ethyl icosapentate is present in a pharmaceutical composition and the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 
     
     
         5 . The method of  claim 4 , wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 
     
     
         6 . The method of  claim 1 , wherein the subject is administered the icosapent ethyl for a period of at least about 2 years. 
     
     
         7 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 5%. 
     
     
         8 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 10%. 
     
     
         9 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 15%. 
     
     
         10 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 20%.

Join the waitlist — get patent alerts

Track US2021100764A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.